[go: up one dir, main page]

WO2008115259A3 - Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases - Google Patents

Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases Download PDF

Info

Publication number
WO2008115259A3
WO2008115259A3 PCT/US2007/075511 US2007075511W WO2008115259A3 WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3 US 2007075511 W US2007075511 W US 2007075511W WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3
Authority
WO
WIPO (PCT)
Prior art keywords
ubiquitination
pharmaceutical compositions
compounds
treatment
useful
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/075511
Other languages
French (fr)
Other versions
WO2008115259A2 (en
Inventor
Rajinder Singh
Usha Ramesh
Jianing Huang
Sarkiz D Issakani
Lyuben Tsvetkov
Matthew David Petroski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rigel Pharmaceuticals Inc
Original Assignee
Rigel Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals Inc filed Critical Rigel Pharmaceuticals Inc
Publication of WO2008115259A2 publication Critical patent/WO2008115259A2/en
Publication of WO2008115259A3 publication Critical patent/WO2008115259A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.
PCT/US2007/075511 2006-08-10 2007-08-08 Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases Ceased WO2008115259A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US82205006P 2006-08-10 2006-08-10
US60/822,050 2006-08-10
US88758507P 2007-01-31 2007-01-31
US60/887,585 2007-01-31

Publications (2)

Publication Number Publication Date
WO2008115259A2 WO2008115259A2 (en) 2008-09-25
WO2008115259A3 true WO2008115259A3 (en) 2008-12-18

Family

ID=39708865

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/075511 Ceased WO2008115259A2 (en) 2006-08-10 2007-08-08 Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases

Country Status (1)

Country Link
WO (1) WO2008115259A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658962B (en) * 2017-03-30 2021-10-01 复旦大学 3-Substituted coumarin furoxan derivatives and their use in the preparation of anti-multidrug-resistant tumor drugs

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA99448C2 (en) 2006-11-27 2012-08-27 Х. Луннбэк А/С Heteroaryl amide derivatives
US12240854B2 (en) 2018-03-22 2025-03-04 Helmholtz Zentrum Muenchen—Deutsches Forschungszentrum Fuergesundheit Und Umwelt (Gmbh) TRAF 6 inhibitors

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006002284A1 (en) * 2004-06-22 2006-01-05 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108658962B (en) * 2017-03-30 2021-10-01 复旦大学 3-Substituted coumarin furoxan derivatives and their use in the preparation of anti-multidrug-resistant tumor drugs

Also Published As

Publication number Publication date
WO2008115259A2 (en) 2008-09-25

Similar Documents

Publication Publication Date Title
WO2005007621A3 (en) Ubiquitin ligase inhibitors
WO2005037845A8 (en) Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors
WO2008013838A3 (en) Pyridizinone derivatives
EP2573069A3 (en) Inhibitors of histone deacetylase and prodrugs thereof
WO2008055068A3 (en) Inhibitors of histone deacetylase
WO2007089634A3 (en) Inhibitors of fatty acid synthase (fas)
WO2006113919A3 (en) Aryl alkyl acid derivatives for and use thereof
WO2007109178A3 (en) Indole derivatives as inhibitors of histone deacetylase
WO2007097931A3 (en) Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2009097113A3 (en) Oxazole and thiazole compounds as b-catenin modulators and uses thereof
WO2007092213A3 (en) Inhibitors of e1 activating enzyme
WO2005111039A3 (en) Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase
WO2008049123A3 (en) 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases
WO2008021038A3 (en) Pyridobenzazepine compounds and methods for inhibiting mitotic progression
NO20092569L (en) Inhibitors of Akt activity
WO2008019124A8 (en) Heteroaryl compounds useful as inhibitors of e1 activating enzymes
WO2007087231A3 (en) Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes
WO2010009139A3 (en) Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors
WO2008118391A3 (en) Triazinone and diazinone derivatives useful as hsp90 inhibitors
WO2006091395A3 (en) Inhibitors of akt activity
WO2006135627A3 (en) Inhibitors of akt activity
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
WO2010017035A3 (en) Inhibitors of iap
WO2008061724A3 (en) Compositions comprising carnosic acid 12-methylether
WO2007011760A3 (en) Inhibitors of mitotic kinesin

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07874455

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

NENP Non-entry into the national phase

Ref country code: RU

122 Ep: pct application non-entry in european phase

Ref document number: 07874455

Country of ref document: EP

Kind code of ref document: A2